Skip to content
OpenCapital
Get started

Palvella Therapeutics PVLA Q1 2025 Annual earnings

Reported May 15, 2025 · Before market open

EPS-$0.74Beat by $2.66
EPS estimate-$3.40

Next report

Aug 13, 2026 (In 2 weeks)
EPS estimate-$1.16

Financials

Q1 2025

Income statement

See full
Operating income-$7.9M-347%
Net income-$8.2M-223%
EPS (diluted)-$0.74+51.9%

Balance sheet

See full
Cash & equivalents$75.6M+296%
Total equity$55.6M+172%
Total assets$79.4M+169%

Cash flow

See full
Operating cash flow-$6.8M-514%

Versus estimates

Diluted EPS

Q1 2026-$1.20Miss by $0.30Q4 2025-$1.08Miss by $0.17Q3 2025-$1.03Miss by $0.18Q2 2025-$0.86Miss by $0.08
Q1 2025-$0.74Beat by $2.66
Q4 2024$4.00Beat by $4.39

Ask the moment Palvella Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Palvella Therapeutics report Q1 2025 earnings?
Palvella Therapeutics (PVLA) reported Q1 2025 earnings on May 15, 2025 before market open.
What were Palvella Therapeutics's Q1 2025 revenue and EPS?
Palvella Therapeutics reported eps of $-0.74 for Q1 2025.
Did Palvella Therapeutics beat estimates in Q1 2025?
EPS beat the consensus estimate of $-3.40 by $2.66.
How did Palvella Therapeutics's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 63.0% from $-2.00.
Where can I find Palvella Therapeutics's Q1 2025 SEC filings?
You can read the 10-K periodic report (0000950170-25-047212) directly on SEC EDGAR. The filing index links above go to sec.gov.